XML 68 R27.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segments of business and geographic areas
 12 Months Ended
Dec. 29, 2024
Segment Reporting [Abstract]  
Segments of business and geographic areas Segments of business and geographic areas
Following the separation of the Consumer Health business in the fiscal third quarter of 2023, the Company is now organized into two reportable segments: Innovative Medicine and MedTech. The segment results have been recast for all periods to reflect the continuing operations of the Company.
The Company’s chief operating decision maker (CODM) is the Chief Executive Officer (Principal Executive Officer). For the Innovative Medicine and MedTech segments, the CODM uses segment income before tax to allocate resources (including employees, financial, and capital resources) for each segment predominantly in the annual forecasting process. The CODM considers planning-to-actual variances on a quarterly basis to assess performance and make decisions about allocating resources to the segments.
 Sales to Customers % Change
(Dollars in Millions)202420232022’24 vs. ’23’23 vs. ’22
INNOVATIVE MEDICINE
Immunology
U.S.$11,35511,53911,036(1.6)%4.6 
International6,4736,5135,899(0.6)10.4 
Worldwide17,82818,05216,935(1.2)6.6 
REMICADE
U.S.1,0091,1431,417(11.7)(19.3)
U.S. Exports98147204(33.0)(28.0)
International497549722(9.5)(23.9)
Worldwide1,6051,8392,343(12.8)(21.5)
SIMPONI / SIMPONI ARIA
U.S.1,0821,1241,166(3.8)(3.6)
International1,1081,0731,0173.3 5.4 
Worldwide2,1902,1972,184(0.3)0.6 
STELARA
U.S.6,7206,9666,388(3.5)9.0 
International3,6413,8923,335(6.4)16.7 
Worldwide10,36110,8589,723(4.6)11.7 
TREMFYA
U.S.2,4432,1471,84413.7 16.5 
International1,22799982422.8 21.2 
Worldwide3,6703,1472,66816.6 17.9 
OTHER IMMUNOLOGY
U.S.31117(74.1)(33.8)
International000— —
Worldwide31117(74.1)(33.8)
Infectious Diseases
U.S.1,3541,5001,680(9.8)(10.7)
International2,0422,9183,769(30.0)(22.6)
Worldwide3,3964,4185,449(23.1)(18.9)
COVID-19 VACCINE
U.S.00120—*
International1981,1172,059(82.4)(45.8)
 Sales to Customers % Change
(Dollars in Millions)202420232022’24 vs. ’23’23 vs. ’22
Worldwide1981,1172,179(82.4)(48.8)
EDURANT / rilpivirine
U.S.313536(10.0)(3.7)
International1,2411,11597211.2 14.8 
Worldwide1,2721,1501,00810.6 14.1 
PREZISTA / PREZCOBIX /
REZOLSTA / SYMTUZA
U.S.1,3111,4461,494(9.4)(3.2)
International401408449(1.7)(9.2)
Worldwide1,7121,8541,943(7.7)(4.6)
OTHER INFECTIOUS DISEASES
U.S.111930(41.0)(34.5)
International203278289(26.7)(3.8)
Worldwide214297318(27.6)(6.7)
Neuroscience
U.S.4,3984,0653,5708.2 13.9 
International2,7183,0763,323(11.6)(7.5)
Worldwide7,1157,1406,893(0.4)3.6 
CONCERTA / methylphenidate
U.S.134230151(41.7)52.5 
International507554493(8.4)12.2 
Worldwide641783644(18.1)21.6 
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
U.S.3,1252,8972,7147.9 6.7 
International1,0971,2181,426(9.9)(14.6)
Worldwide4,2224,1154,1402.6 (0.6)
SPRAVATO
U.S.92958932857.8 79.7 
International1481004648.2 *
Worldwide1,07768937456.4 84.1 
OTHER NEUROSCIENCE
U.S.210349376(39.8)(7.3)
International9651,2041,358(19.8)(11.3)
Worldwide1,1751,5531,734(24.3)(10.4)
Oncology
U.S.10,8548,4626,93028.3 22.1 
International9,9269,1999,0527.9 1.6 
Worldwide20,78117,66115,98317.7 10.5 
CARVYKTI
U.S.86946913385.2*
International9430—**
 Sales to Customers % Change
(Dollars in Millions)202420232022’24 vs. ’23’23 vs. ’22
Worldwide96350013392.7*
DARZALEX
U.S.6,5885,2774,21024.8 25.4 
International5,0824,4673,76713.8 18.6 
Worldwide11,6709,7447,97719.8 22.2 
ERLEADA
U.S.1,2821,06596820.3 10.0 
International1,7171,32291329.8 44.8 
Worldwide2,9992,3871,88125.6 26.9 
IMBRUVICA
U.S.1,0201,0511,390(3.0)(24.4)
International2,0182,2142,394(8.8)(7.5)
Worldwide3,0383,2643,784(6.9)(13.7)
TECVAYLI
U.S.4183341225.3 *
International131613**
Worldwide5493951538.8 *
ZYTIGA /abiraterone acetate
U.S.345074(32.2)(32.1)
International5978371,696(28.6)(50.7)
Worldwide6318871,770(28.8)(49.9)
OTHER ONCOLOGY
U.S.643215144*49.3 
International2882692807.1 (3.9)
Worldwide93148442392.5 14.4 
Pulmonary Hypertension
U.S.3,1432,6972,34616.5 15.0 
International1,1401,1171,0712.0 4.3 
Worldwide4,2823,8153,41712.3 11.6 
OPSUMIT
U.S.1,5201,2921,13217.7 14.1 
International664681651(2.4)4.6 
Worldwide2,1841,9731,78310.7 10.6 
UPTRAVI
U.S.1,5111,3261,10413.9 20.1 
International30725521820.1 17.3 
Worldwide1,8171,5821,32214.9 19.7 
OTHER PULMONARY HYPERTENSION
U.S.1127911041.8 (28.6)
International169182202(6.9)(10.3)
Worldwide2812603137.9 (16.7)
 Sales to Customers % Change
(Dollars in Millions)202420232022’24 vs. ’23’23 vs. ’22
Cardiovascular / Metabolism / Other
U.S.2,8662,9063,042(1.4)(4.5)
International696765845(9.1)(9.4)
Worldwide3,5623,6713,887(3.0)(5.5)
XARELTO
U.S.2,3732,3652,4730.3 (4.4)
International———— — 
Worldwide2,3732,3652,4730.3 (4.4)
OTHER
U.S.494541569(8.8)(5.0)
International696765845(9.1)(9.4)
Worldwide1,1891,3061,414(8.9)(7.6)
TOTAL INNOVATIVE MEDICINE
U.S.33,97031,16928,6049.0 9.0 
International22,99423,59023,959(2.5)(1.5)
Worldwide56,96454,75952,5634.0 4.2 
MEDTECH
Cardiovascular (1)
U.S.4,5133,6332,16924.2 67.5 
International3,1942,7172,13117.6 27.5 
Worldwide7,7076,3504,30021.4 47.7 
ELECTROPHYSIOLOGY
U.S.2,7382,4582,03611.4 20.7 
International2,5292,2301,90113.4 17.3 
Worldwide5,2674,6883,93712.3 19.1 
ABIOMED(2)
U.S.1,2131,0663113.7 *
International284240—18.2 *
Worldwide1,4961,3063114.5 *
SHOCKWAVE(3)
U.S.442——**
International122——**
Worldwide564——**
OTHER CARDIOVASCULAR(1)
U.S.12010910210.7 6.7 
International2602472305.3 7.3 
Worldwide3803563326.9 7.1 
Orthopaedics
U.S.5,6895,5255,3213.0 3.8 
International3,4703,4173,2671.5 4.6 
Worldwide9,1588,9428,5872.4 4.1 
 Sales to Customers % Change
(Dollars in Millions)202420232022’24 vs. ’23’23 vs. ’22
HIPS
U.S.1,0579969436.2 5.6 
International5815645713.0 (1.2)
Worldwide1,6381,5601,5145.0 3.0 
KNEES
U.S.9228968512.9 5.3 
International62355950811.3 10.2 
Worldwide1,5451,4561,3596.1 7.1 
TRAUMA
U.S.2,0131,9491,8823.3 3.6 
International1,0361,0309890.6 4.1 
Worldwide3,0492,9792,8712.3 3.8 
SPINE, SPORTS & OTHER
U.S.1,6961,6841,6450.7 2.4 
International1,2301,2631,198(2.6)5.4 
Worldwide2,9262,9472,843(0.7)3.7 
Surgery
U.S.4,0034,0313,897(0.7)3.4 
International5,8426,0065,793(2.7)3.7 
Worldwide9,84510,0379,690(1.9)3.6 
ADVANCED
U.S.1,8381,8331,7840.2 2.8 
International2,6502,8372,785(6.6)1.9 
Worldwide4,4884,6714,569(3.9)2.2 
GENERAL
U.S.2,1652,1982,113(1.5)4.0 
International3,1923,1683,0080.8 5.3 
Worldwide5,3585,3665,121(0.2)4.8 
Vision
U.S.2,1282,0861,9902.0 4.8 
International3,0182,9862,8591.1 4.5 
Worldwide5,1465,0724,8491.5 4.6 
CONTACT LENSES / OTHER
U.S.1,6841,6261,5223.6 6.8 
International2,0492,0762,022(1.3)2.7 
Worldwide3,7333,7023,5430.8 4.5 
SURGICAL
U.S.444460468(3.4)(1.8)
International9699108376.5 8.6 
Worldwide1,4131,3701,3063.2 4.9 
 Sales to Customers % Change
(Dollars in Millions)202420232022’24 vs. ’23’23 vs. ’22
TOTAL MEDTECH   
U.S.16,33215,27513,3776.9 14.2 
International15,52515,12514,0502.6 7.7 
Worldwide31,85730,40027,4274.8 10.8 
WORLDWIDE   
U.S.50,30246,44441,9818.3 10.6 
International38,51938,71538,009(0.5)1.9 
Worldwide$88,82185,15979,9904.3 %6.5 
*    percentage greater than 100% or not meaningful
(1)Previously referred to as Interventional Solutions
(2)Acquired on December 22, 2022
(3)Acquired on May 31, 2024
Income Before Tax by Segment
(Dollars in Millions)
2024 (3)
2023 (4)
2022 (5)
Innovative
Medicine		MedTechTotalInnovative
Medicine		MedTechTotalInnovative
Medicine		MedTechTotal
Sales to customers$56,96431,85754,75930,40052,56327,427
Cost of products sold14,03613,34513,71512,72214,06610,397
Selling, marketing and administrative 10,90610,8129,84210,4769,7149,537
Research and development expense13,5293,70311,9633,12211,6422,493
Other segment items (1)
(426)257993(589)1,494553
Segment income before tax$18,9193,74022,65918,2464,66922,91515,6474,44720,094
Less: Expense not allocated to segments (2)
5,9727,853735
Worldwide total$16,68715,06219,359
 Identifiable Assets
(Dollars in Millions)20242023
Innovative Medicine$57,07058,324
MedTech84,32274,710
Total141,392133,034
General corporate (6)
38,71234,524
Worldwide total$180,104167,558
Additions to Property,
Plant & Equipment		Depreciation and
Amortization
(Dollars in Millions)202420232022202420232022
Innovative Medicine$1,7101,6531,374$3,7603,8473,687
MedTech2,4432,3722,1203,2372,9432,302
Segments total4,1534,0253,4946,9976,7905,989
Discontinued operations—162303—383641
General corporate271356212342313340
Worldwide total$4,4244,5434,009$7,3397,4866,970
 Sales to Customers
Long-Lived Assets (7)
(Dollars in Millions)20242023202220242023
United States$50,30246,44441,981$70,67054,832
Europe20,21220,41020,66427,26731,616
Western Hemisphere excluding U.S. 4,7144,5494,1081,7281,491
Asia-Pacific, Africa13,59313,75613,2371,4541,500
Segments total88,82185,15979,990101,11989,439
General corporate1,2171,192
Other non long-lived assets77,76876,927
Worldwide total$88,82185,15979,990$180,104167,558
See Note 1 for a description of the segments in which the Company operates.
Export sales are not significant. In fiscal year 2024, the Company utilized three wholesalers distributing products for both segments that represented approximately 20.5%, 15.6% and 12.3% of the total gross revenues. In fiscal year 2023, the Company had three wholesalers distributing products for both segments that represented approximately 18.2%, 15.1% and 14.2% of the total gross revenues. In fiscal year 2022, the Company had three wholesalers distributing products for all three segments that represented approximately 18.9%, 15.0%, and 13.8% of the total gross revenues.
(1)Other segment expenses for each reportable segment include charges related to other income and expenses, restructuring activities and impairment charges related to in-process research and development.
(2)Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal years 2024 and 2023 include charges for talc matters of approximately $5.1 billion and $7 billion, respectively (See Note 19, Legal proceedings, for additional details). The fiscal year 2024 includes a loss of approximately $0.4 billion related to the debt to equity exchange of the Company's remaining shares of Kenvue Common Stock. The fiscal year 2023 includes the unfavorable change in the fair value of the retained stake in Kenvue of approximately $0.4 billion.
(3)Innovative Medicine segment income before tax includes:
•Acquired in-process research & development expense of $1.25 billion to secure the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition)
•Monetization of royalty rights of $0.3 billion
•Litigation expense of $0.3 billion primarily related to Risperdal Gynecomastia
•An intangible asset impairment charge of approximately $0.2 billion associated with the M710 (biosimilar) asset acquired as part of the acquisition of Momenta Pharmaceuticals in 2020.
•A restructuring related charge of $0.1 billion
•One-time COVID-19 Vaccine manufacturing exit related costs of $0.1 billion
•Favorable changes in the fair value of securities of $0.1 billion
MedTech segment income before tax includes:
•Acquisition and integration related costs of $1.0 billion primarily related to the acquisition of Shockwave
•Acquired in-process research and development expense of $0.5 billion from the V-Wave acquisition
•A gain of $0.2 billion related to the Acclarent divestiture
•A Medical Device Regulation charge of $0.2 billion
•A restructuring related charge of $0.2 billion
(4)Innovative Medicine segment income before tax includes:
•One-time COVID-19 Vaccine manufacturing exit related costs of $0.7 billion
•A restructuring related charge of $0.5 billion
•Unfavorable changes in the fair value of securities of $0.4 billion
•Favorable litigation related items of $0.1 billion
•Loss on divestiture of $0.2 billion.
•An intangible asset impairment charge of approximately $0.2 billion related to market dynamics associated with a non-strategic asset (M710) acquired as part of the acquisition of Momenta Pharmaceuticals in 2020.
MedTech segment income before tax includes:
•Acquired in-process research and development expense of $0.4 billion related to the Laminar acquisition in 2023
•A restructuring related charge of $0.3 billion
•Acquisition and integration related costs of $0.2 billion primarily related to the acquisition of Abiomed
•A Medical Device Regulation charge of $0.3 billion
•Income from litigation settlements of $0.1 billion
(5)Innovative Medicine segment income before tax includes:
•One-time COVID-19 Vaccine manufacturing exit related costs of $1.5 billion
•An intangible asset impairment charge of approximately $0.8 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS) acquired with the acquisition of XBiotech, Inc. in the fiscal year 2020. Additional information regarding efficacy of the AD and HS indications became available which led the Company to the decision to terminate the development of bermekimab for AD and HS
•Litigation expense of $0.1 billion
•Unfavorable changes in the fair value of securities of $0.7 billion
•A restructuring related charge of $0.1 billion
MedTech segment income before tax includes:
•Litigation expense of $0.6 billion primarily for pelvic mesh related costs
•A restructuring related charge of $0.3 billion
•Acquisition and integration related costs of $0.3 billion primarily related to the acquisition of Abiomed
•A Medical Device Regulation charge of $0.3 billion
(6) General corporate includes cash, cash equivalents, marketable securities and other corporate assets.
(7)Long-lived assets include property, plant and equipment, net for fiscal years 2024, and 2023 of $20,518 and $19,898, respectively, and intangible assets and goodwill, net for fiscal years 2024 and 2023 of $81,818 and $70,733, respectively.